Neurocrine Biosciences, Inc.

NasdaqGS:NBIX

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

🧠 Mental Health

💊 Pharmaceuticals

Location

United States

Market Cap

USD 12.52 B

Share Price

USD 126.55

Avg Daily Volume

1,513,903

Change (1 day)

-0.60%

Change (1 year)

-5.61%

Change (YTD)

-7.29%

Neurocrine Biosciences, Inc. Common Stock Issued for the Trailing 12 Months (TTM) ending March 31, 2025: USD 74.30 M

Neurocrine Biosciences, Inc. Common Stock Issued is USD 74.30 M for the Trailing 12 Months (TTM) ending March 31, 2025, a -41.50% change year over year. Common stock issued is cash received from issuing new shares of the company’s common stock.

Neurocrine Biosciences, Inc. Common Stock Issued for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 127.00 M, a 128.42% change year over year.
Neurocrine Biosciences, Inc. Common Stock Issued for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 55.60 M, a 65.48% change year over year.
Neurocrine Biosciences, Inc. Common Stock Issued for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 33.60 M, a -18.05% change year over year.
Neurocrine Biosciences, Inc. Common Stock Issued for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 41.00 M, a 46.51% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Common Stock Issued	Common Stock Repurchased	Free Cash Flow	Operating Cash Flow

NasdaqGS: NBIX

Neurocrine Biosciences, Inc.

CEO	Mr. Kyle W. Gano Ph.D.
IPO Date	May 23, 1996
Location	United States
Headquarters	12780 El Camino Real
Employees	1,800
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 🧠 Mental Health 💊 Pharmaceuticals

Description

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.